Intersect ENT, Inc. (XENT)
(Delayed Data from NSDQ)
$33.65 USD
+1.22 (3.76%)
Updated May 3, 2019 04:00 PM ET
After-Market: $33.66 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$33.65 USD
+1.22 (3.76%)
Updated May 3, 2019 04:00 PM ET
After-Market: $33.66 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Sientra (SIEN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sientra (SIEN) delivered earnings and revenue surprises of -11.54% and 5.67%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Intersect ENT (XENT) Q1 Earnings & Revenues Miss Estimates
by Zacks Equity Research
Intersect ENT (XENT) records lower-than-expected revenues for the first quarter, with mounting operating costs impacting the bottom line.
DexCom (DXCM) Misses Q1 Earnings Estimates
by Zacks Equity Research
DexCom (DXCM) delivered earnings and revenue surprises of -36% and 1.47%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
SeaSpine Holdings (SPNE) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
SeaSpine (SPNE) delivered earnings and revenue surprises of -44.44% and 1.33%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
OrthoPediatrics (KIDS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
OrthoPediatrics (KIDS) delivered earnings and revenue surprises of 17.24% and 0.13%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Teleflex (TFX) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Teleflex (TFX) delivered earnings and revenue surprises of 1.98% and 1.87%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
TransMedics (TMDX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
TransMedics (TMDX) delivered earnings and revenue surprises of -6.98% and 26.21%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Why Is Intersect ENT (XENT) Down 0.6% Since Last Earnings Report?
by Zacks Equity Research
Intersect ENT (XENT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Intersect ENT's (XENT) Sell-Off on Track Amid COVID Woes
by Zacks Equity Research
Amid industry-wide concerns of deferral of elective procedures, Intersect ENT's (XENT) plans to consolidate with an industry behemoth like Medtronic seems a strategically aligned survival plan.
Intersect ENT (XENT) Q3 Loss Widens, Sell-Off Process On Track
by Zacks Equity Research
An increase in Intersect ENT's (XENT) operating costs puts pressure on its Q3 bottom line.
Intersect ENT (XENT) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Intersect ENT (XENT) delivered earnings and revenue surprises of -14.29% and -17.66%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Intersect ENT (XENT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Intersect ENT (XENT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MedTech Thrives on M&A Frenzy: 3 Stocks to Focus on
by Debanjana Dey
MedTech stocks like Boston Scientific (BSX), Catalent (CTLT) and Baxter (BAX) are likely to solidify businesses on the back of impressive M&As.
Medtronic (MDT) Starts Pediatric Trial for Scoliosis Treatment
by Zacks Equity Research
Medtronic's (MDT) BRAIVE IDE study will assess the safety and efficacy of growth modulation system in correcting the spine's curve in patients with juvenile or adolescent idiopathic scoliosis.
Intersect ENT's (XENT) Sell Off Plan Strategic Amid Pandemic
by Zacks Equity Research
Intersect ENT's (XENT) top-line growth from the PROPEL family of products and SINUVA continues to be challenged by seasonal variations in the volume of sinus surgery procedures.
Medtronic (MDT) to Expand Neuroscience Line With XENT Buyout
by Zacks Equity Research
Medtronic's (MDT) acquisition of Intersect ENT is intended to offer a wide-ranging variety of solutions to help surgeons treat CRS patients.
Intersect ENT (XENT) Q2 Loss Wider Than Expected, Revenues Top
by Zacks Equity Research
Intersect ENT's (XENT) second-quarter revenues improved year over year on increased PROPEL and SINUVA sales.
Intersect ENT (XENT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Intersect ENT (XENT) delivered earnings and revenue surprises of -16.67% and 0.47%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Intersect ENT (XENT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Intersect ENT (XENT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Intersect ENT (XENT) Surges 5.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
Intersect ENT (XENT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
5 Probable MedTech Winners Post-COVID on Discounted PEG
by Zacks Equity Research
Here are some MedTech stocks with favorable PEG ratio, which are expected to provide gains in 2021.
Why Is Intersect ENT (XENT) Down 10.8% Since Last Earnings Report?
by Zacks Equity Research
Intersect ENT (XENT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Intersect ENT (XENT) Receives CE Mark for PROPEL Contour
by Zacks Equity Research
The CE Mark approval is backed by positive results from Intersect ENT's (XENT) PROGRESS clinical study of the PROPEL Contour.
Intersect ENT (XENT) Q1 Loss Wider Than Expected, Revenues Top
by Zacks Equity Research
Intersect ENT (XENT) first-quarter revenues improved year over year on increased PROPEL and SINUVA sales.
Intersect ENT (XENT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Intersect ENT (XENT) delivered earnings and revenue surprises of -21.43% and 4.43%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?